ACET

Adicet Bio, Inc. [ACET] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

ACET Stock Summary

Top 10 Correlated ETFs

ACET


Top 10 Correlated Stocks

ACET


In the News

02:28 29 Mar 2024 ACET

The Penny Stock A-List: 7 High-Profile Companies on the Verge of Greatness

In most cases, investors should stay away from penny stocks. They're wild, they're unpredictable and they tend to lose their stakeholders money more so than they return.

10:36 29 Mar 2024 ACET

Adicet Bio (ACET) Loses -16.39% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Adicet Bio (ACET) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

09:53 29 Mar 2024 ACET

ACET Stock Earnings: Adicet Bio Meets EPS for Q4 2023

Adicet Bio (NASDAQ: ACET ) just reported results for the fourth quarter of 2023. Adicet Bio reported earnings per share of -69 cents.

10:41 29 Mar 2024 ACET

Are Medical Stocks Lagging Adicet Bio (ACET) This Year?

Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

07:00 29 Mar 2024 ACET

Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference being held March 26, 2024. Details of the event are as follows: Date: Tuesday, March 26, 2024 Time: 10.

11:25 29 Mar 2024 ACET

3 High-Risk Stocks That Could Pay Off in the Millions

High-risk stocks could potentially turn the tables for investors willing to stomach the risk. Moreover, as the Nasdaq Composite hit a fresh high last Friday, ahead of its 2021 peak, the market's appetite for risk continues to grow.

10:46 29 Mar 2024 ACET

Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year?

Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

06:53 29 Mar 2024 ACET

7 Top-Tier Penny Stocks for a Smart Bet

Penny stocks are heating up as the S&P 500 hits new highs, signaling opportunity. With the S&P 500 posting new highs multiple times in the past few months and prospects of lower interest rates, the stage is set for potentially lucrative penny stock investments.

01:37 29 Mar 2024 ACET

7 Biotech Penny Stocks on the Verge of Clinical Trial Victory

While targeting the therapeutic side of the healthcare sector can be quite lucrative, nothing matches the excitement of biotech penny stocks. Of course, the excitement goes toward both extremes of the emotional spectrum.

10:41 29 Mar 2024 ACET

Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?

Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

ACET Financial details

Company Rating
Neutral
Market Cap
179.92M
Income
-140.02M
Revenue
-24.99M
Book val./share
4.53
Cash/share
4.26
Dividend
-
Dividend %
-
Employees
143
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-1.06
Forward P/E
-1.14
PEG
-0.17
P/S
-5.96
P/B
0.76
P/C
0.55
P/FCF
-1.49
Quick Ratio
9.27
Current Ratio
9.4
Debt / Equity
0.11
LT Debt / Equity
0.1
-
-
EPS (TTM)
-3.27
EPS next Y
-2.06
EPS next Q
-0.49
EPS this Y
-18.5%
EPS next Y
-37.05%
EPS next 5Y
-42.05%
EPS last 5Y
28.24%
Revenue last 5Y
25.02%
Revenue Q/Q
-
EPS Q/Q
54.67%
-
-
-
-
SMA20
-
SMA50
-33.33%
SMA100
100%
Inst Own
72.45%
Inst Trans
0.85%
ROA
-60%
ROE
763%
ROC
-0.71%
Gross Margin
100%
Oper. Margin
608%
Profit Margin
560%
Payout
-
Shs Outstand
82.15M
Shs Float
67.15M
-
-
-
-
Target Price
32.5
52W Range
1.1-7.5
52W High
-66.43%
52W Low
+135%
RSI
53
Rel Volume
0.28
Avg Volume
1.81M
Volume
497K
Perf Week
9.81%
Perf Month
-21.67%
Perf Quarter
82.17%
Perf Half Y
64.34%
-
-
-
-
Beta
1.63
-
-
Volatility
0.1%, 0.22%
Prev Close
0%
Price
2.35
Change
0.86%

ACET Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.420.052.450.310.61
Net income per share
-0.47-1.44-5.01-2-1.63
Operating cash flow per share
-0.93-1.42-5.68-1.65-1.09
Free cash flow per share
-0.97-1.48-5.81-2.07-1.5
Cash per share
5.513.1912.938.976.27
Book value per share
5.32-3.08-14.53-5.44-5.8
Tangible book value per share
5.32-3.0812.19.166.64
Share holders equity per share
5.32-3.08-14.53-5.44-5.8
Interest debt per share
002.970.680.51
Market cap
1.18B204.32M102.85M541.35M367.26M
Enterprise value
1.17B193.71M40.15M284.75M130.62M
P/E ratio
-127.11-7.26-2.8-8.73-5.48
Price to sales ratio
144.49205.355.7455.6414.7
POCF ratio
-65.02-7.33-2.48-10.6-8.2
PFCF ratio
-62.03-7.06-2.42-8.45-5.97
P/B Ratio
11.34-3.38-0.97-3.22-1.54
PTB ratio
11.34-3.38-0.97-3.22-1.54
EV to sales
143.63194.692.2429.275.23
Enterprise value over EBITDA
-135.59-7.21-1.02-4.6-1.87
EV to operating cash flow
-64.63-6.95-0.97-5.58-2.92
EV to free cash flow
-61.66-6.69-0.94-4.44-2.12
Earnings yield
-0.01-0.14-0.36-0.11-0.18
Free cash flow yield
-0.02-0.14-0.41-0.12-0.17
Debt to equity
00-0.2-0.12-0.09
Debt to assets
000.140.060.06
Net debt to EBITDA
0.810.391.594.143.39
Current ratio
19.164.326.7717.3113.25
Interest coverage
00-292.47-349.05-906.89
Income quality
1.960.991.130.820.64
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
1.038.741.272.281.05
Research and developement to revenue
1.823.811.925.032.85
Intangibles to total assets
000.140.060.06
Capex to operating cash flow
0.050.040.020.260.37
Capex to revenue
-0.11-1.08-0.06-1.34-0.67
Capex to depreciation
-0.72-0.86-0.81-8.48-6.52
Stock based compensation to revenue
0.31.180.291.290.69
Graham number
7.549.9840.4715.6614.59
ROIC
-0.140.520.580.480.36
Return on tangible assets
-0.08-0.34-0.28-0.19-0.22
Graham Net
5.22-4.016.987.895.38
Working capital
103.82M49.32M80.63M266.12M241.33M
Tangible asset value
104.2M-60.37M88.55M283.67M272.88M
Net current asset value
103.8M-77.77M50.61M246.63M222.69M
Invested capital
00-0.2-0.12-0.09
Average receivables
130.44M467.5K1.83M1.47M324.5K
Average payables
45.01M526K1.3M2.41M3.83M
Average inventory
68.19M336K-1.21M792K3.62M
Days sales outstanding
0342.9955.688.036.35
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
01.066.5645.4757.45
Payables turnover
00000
Inventory turnover
00000
ROE
-0.090.470.340.370.28
Capex per share
-0.04-0.05-0.14-0.42-0.41

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0-0.6000
Net income per share
-0.5-0.67-0.69-0.75-1.16
Operating cash flow per share
-0.37-0.45-0.56-0.58-0.49
Free cash flow per share
-0.48-0.61-0.61-0.61-0.52
Cash per share
6.796.195.44.784.26
Book value per share
7.63-5.72-6.275.574.53
Tangible book value per share
7.166.555.755.114.53
Share holders equity per share
7.63-5.72-6.275.574.53
Interest debt per share
0.520.510.550.530.51
Market cap
592.16M372.36M247.05M104.39M58.88M
Enterprise value
331.2M135.73M38.91M-78.43M-102.58M
P/E ratio
-7.05-3.31-2.08-0.81-0.3
Price to sales ratio
0-14.9000
POCF ratio
-38.63-19.77-10.25-4.19-2.77
PFCF ratio
-29.4-14.7-9.5-3.95-2.66
P/B Ratio
1.86-1.56-0.920.440.3
PTB ratio
1.86-1.56-0.920.440.3
EV to sales
0-5.43000
Enterprise value over EBITDA
-15.61-4.55-1.262.543.56
EV to operating cash flow
-21.61-7.21-1.613.154.83
EV to free cash flow
-16.45-5.36-1.52.974.63
Earnings yield
-0.04-0.08-0.12-0.31-0.85
Free cash flow yield
-0.03-0.07-0.11-0.25-0.38
Debt to equity
0.07-0.09-0.090.090.11
Debt to assets
0.060.060.080.080.09
Net debt to EBITDA
12.37.936.745.925.61
Current ratio
16.5913.2512.9811.089.4
Interest coverage
-1.28K-1.21K-1.75K-8.72K-52.26K
Income quality
0.70.630.780.770.43
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0-0.26000
Research and developement to revenue
0-1000
Intangibles to total assets
0.050.060.060.070
Capex to operating cash flow
0.310.340.080.060.04
Capex to revenue
00.26000
Capex to depreciation
-6.34-6.13-1.53-1-0.55
Stock based compensation to revenue
0-0.17000
Graham number
9.39.329.879.7210.88
ROIC
-0.060.150.14-0.12-0.22
Return on tangible assets
-0.06-0.09-0.1-0.13-0.21
Graham Net
5.915.34.533.923.39
Working capital
268.52M241.33M216.71M189.82M166.12M
Tangible asset value
298.2M272.88M246.75M219.6M194.68M
Net current asset value
249.09M222.69M196.05M170.08M147.3M
Invested capital
0.07-0.09-0.090.090.11
Average receivables
144K361.5K501K603K329.5K
Average payables
4.36M4.49M3.58M2.93M3.59M
Average inventory
-129.5K1.15M2.33M2.08M2.15M
Days sales outstanding
0-1.57000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
0-57.45000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.070.120.11-0.14-0.26
Capex per share
-0.12-0.16-0.04-0.04-0.02

ACET Frequently Asked Questions

What is Adicet Bio, Inc. stock symbol ?

Adicet Bio, Inc. is a US stock , located in Boston of Ma and trading under the symbol ACET

Is Adicet Bio, Inc. buy or a sell ?

2 stock analysts have 2 predictions with a medium analyst target price of $32.5. The lowest prediction is $27 and the highest is $38

What is ACET stock prediction ?

What is Adicet Bio, Inc. stock quote today ?

Adicet Bio, Inc. stock price is $2.35 today.

Is Adicet Bio, Inc. stock public?

Yes, Adicet Bio, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap